Cite
HARVARD Citation
Tschismarov, R. et al. (2023). Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. Lancet. 401 (10384), pp. 1267-1276. [Online].